Tag: Industry Insights

SPONSORED CONTENT

For 340B program directors, complying with the U.S. Health Resources & Services Administration’s (HRSA’s) requirements is top of mind, all the time. That’s partly because maintaining their employer’s 340B program directly ties to profitability and sometimes survival.  Covered entities need 340B revenue to meet the program’s purpose “to stretch scare resources as far possible, reach more eligible patients and provide more comprehensive services.” Complying with the program requires a constant focus on guidelines and regulations.

Along with protecting program benefits and monitoring changing requirements, 340B program managers also hear politicians, pharmaceutical manufacturers and the press call for more oversight by the federal government. Manufacturers are concerned about program growth.  According to HRSA, discounted purchases under the 340B Program hit $44 billion in 2021, a 16-percent uptick from 2020.  The volume may have slowed down with the recent manufacturer restrictions on use of 340B discounts in the contract pharmacy setting but

SPONSORED CONTENT

As the complexity of managing 340B programs continues to increase, there is a growing need for advanced tools and technologies to ensure compliance integrity and optimize financial stewardship. In this article, we’ll explore the scope of analytics and artificial intelligence (AI) in enhancing 340B programs. By leveraging AI capabilities, such as active decision-making and passive information generation, covered entities can unlock the potential for improved efficiency, accuracy, and cost savings.

Scope of Analytics & AI in 340B

Analytics and AI technologies offer significant opportunities to augment 340B programs and drive better outcomes. Active AI enables the automation of real-time decisions and actions within 340B software, based on pre-defined parameters set by a 340B program expert. While real people are still essential to your 340B program, active AI can be used to make the efforts of your 340B team more effective and efficient.

On the other hand, passive information AI

SPONSORED CONTENT

Are you telling your 340B story? This webinar will teach you how to track the key data points that demonstrate the value of your 340B program. You will learn how to calculate your overall savings, track patient benefits, and create an Impact Profile. You will also learn about the new reporting requirements being passed at the state and federal levels, and how to communicate with lawmakers about the impact of your 340B program.

Key Takeaways:

• Learn how to track the key savings metrics that demonstrate the value of your 340B program.
• Track Patient Benefits to show all the services your CE provides to them.
• Create an Impact Profile that shows the value of your 340B program to your community.
• Stay up-to-date on the latest reporting requirements for 340B programs.
• Learn how to communicate with lawmakers about the impact of your 340B program.

Who Should Attend:

This webinar is for

SPONSORED CONTENT

Today’s U.S. health systems face significant financial challenges. Many are still trying to recoup pandemic-related losses stemming from forced shutdowns, elective procedure postponements, and reduced outpatient visits. These factors have contributed to billions in lost revenue, leaving many of America’s health systems with negative operating margins.

As a result, health systems are desperate to find new ways to maximize cost savings and generate new revenue. Enhancing specialty pharmacy operations is increasingly being recognized as a primary way to achieve this objective in the short term.  A new infographic outlines how therapy expansion, increased specialty drug spending, access challenges, and growing patient need are currently converging to create a unique opportunity for health systems to realize sizable financial gains by evolving their approach to specialty pharmacy.

Manufacturer restrictions create barriers to 340B discounts

Hospital or health system covered entities (CEs) eligible for drug discounts through 340B potentially have